To date, several studies have used [18F]AV1451, which has demonstrated robust pharmacokinetics, high affinity for tau NFTs over amyloid, and minimal non-specific binding, as well as the ability to bind non AD tauopathies. The gene discussed is MAPT; the disease is tauopathy.